Patents by Inventor Ryan FRISCH

Ryan FRISCH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR GUT HEALTH
    Publication number: 20210153521
    Abstract: Provided herein, inter alia, are compositions of organic acid-producing microorganisms and methods of making and using the same to inhibit pathogenic bacterial populations in the gastrointestinal tracts of an animal and additionally promote improvement of one or more metrics in an animal, such as increased bodyweight gain, decreased feed conversion ratio (FCR), improved gut barrier integrity, reduced mortality, reduced pathogen infection, and reduced pathogen shedding in feces.
    Type: Application
    Filed: February 3, 2021
    Publication date: May 27, 2021
    Inventors: TANJA GRUBER, RYAN FRISCH, FELIPE BENDEZU, GERDA SAXER QUANCE
  • GENETIC TARGETING IN NON-CONVENTIONAL YEAST USING AN RNA-GUIDED ENDONUCLEASE
    Publication number: 20200190540
    Abstract: Non-conventional yeasts are disclosed herein comprising at least one RNA-guided endonuclease (RGEN) comprising at least one RNA component that does not have a 5?-cap. This uncapped RNA component comprises a sequence complementary to a target site sequence in a chromosome or episome in the yeast. The RGEN can bind to, and optionally cleave, one or both DNA strands at the target site sequence. An example of an RGEN herein is a complex of a Cas9 protein with a guide RNA. A ribozyme is used in certain embodiments to provide an RNA component lacking a 5?-cap. Further disclosed are methods of genetic targeting in non-conventional yeast.
    Type: Application
    Filed: October 30, 2019
    Publication date: June 18, 2020
    Inventors: Ryan Frisch, Xiaochun Fan, Seung-Pyo Hong
  • Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
    Patent number: 10513711
    Abstract: Non-conventional yeasts are disclosed herein comprising at least one RNA-guided endonuclease (RGEN) comprising at least one RNA component that does not have a 5?-cap. This uncapped RNA component comprises a sequence complementary to a target site sequence in a chromosome or episome in the yeast. The RGEN can bind to, and optionally cleave, one or both DNA strands at the target site sequence. An example of an RGEN herein is a complex of a Cas9 protein with a guide RNA. A ribozyme is used in certain embodiments to provide an RNA component lacking a 5?-cap. Further disclosed are methods of genetic targeting in non-conventional yeast.
    Type: Grant
    Filed: July 5, 2015
    Date of Patent: December 24, 2019
    Assignee: DUPONT US HOLDING, LLC
    Inventors: Ryan Frisch, Xiaochun Fan, Seung-Pyo Hong
  • GENETIC TARGETING IN NON-CONVENTIONAL YEAST USING AN RNA-GUIDED ENDONUCLEASE
    Publication number: 20170226533
    Abstract: Non-conventional yeasts are disclosed herein comprising at least one RNA-guided endonuclease (RGEN) comprising at least one RNA component that does not have a 5?-cap. This uncapped RNA component comprises a sequence complementary to a target site sequence in a chromosome or episome in the yeast. The RGEN can bind to, and optionally cleave, one or both DNA strands at the target site sequence. An example of an RGEN herein is a complex of a Cas9 protein with a guide RNA. A ribozyme is used in certain embodiments to provide an RNA component lacking a 5?-cap. Further disclosed are methods of genetic targeting in non-conventional yeast.
    Type: Application
    Filed: July 5, 2015
    Publication date: August 10, 2017
    Applicant: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: Ryan FRISCH, Xiaochun FAN, Seung-Pyo HONG,